Apellis Pharmaceuticals Files Amended 10-K/A: Key Governance and Executive Compensation Disclosures

WALTHAM, MA – April 28, 2026 — Apellis Pharmaceuticals, Inc. (“Apellis” or the “Company,” Nasdaq: APLS) has filed an Amendment No. 1 on Form 10-K/A with the SEC for its fiscal year ended December 31, 2025. The amendment primarily serves to provide critical Part III information – including details on the Company’s directors, executive officers, corporate governance, and executive compensation – that was previously omitted from its original 10-K filing. This update contains important information for shareholders and may have implications for share value and investor sentiment.

Key Highlights from the 10-K/A Filing

• Purpose of Amendment: The amendment was filed solely to include information required by Items 10 through 14 of Part III of Form 10-K, which covers directors, executive compensation, security ownership, and related party transactions. No definitive proxy statement will be filed within 120 days of fiscal year-end. The amendment does not update financials or other information from the original filing, nor does it reflect subsequent events.
• Corporate Governance Structure:
  • The Company’s board of directors has established an Audit Committee, Compensation Committee, Compliance Committee, and Nominating & Corporate Governance Committee. Each committee operates under a charter (available on the Apellis website) and reviews its charter annually.
  • Directors are required to attend the annual meeting of stockholders, and all directors were present at the 2025 meeting.
  • Governance guidelines specify that a majority of board members must be independent, and the board has adopted a code of business conduct and ethics covering all directors, officers, and employees.
  • The board directly oversees risk management, with committees responsible for specific areas such as compensation risk, audit oversight, and governance practices.
• Executive Compensation Program:
  • The compensation strategy is designed to attract and retain top executive talent, with a strong emphasis on pay-for-performance and alignment with long-term shareholder value.
  • Key compensation elements include:
    • Base Salary: Reviewed annually and benchmarked against industry and peer groups.
    • Annual Cash Incentive Plan: Payouts tied to pre-set quantitative goals, including U.S. product revenues and pipeline advancement.
    • Long-Term Incentive Plan (LTIP): 50% in Performance Stock Units (PSUs) tied to rigorous long-term objectives, and 50% in Restricted Stock Units (RSUs) supporting retention and long-term value creation.
  • Over 94.8% of shareholders supported the 2025 “say-on-pay” advisory vote, reflecting strong investor approval of the Company’s executive compensation practices.
  • The Compensation Committee regularly benchmarks executive pay against a peer group of commercial-stage, pipeline-driven biotech companies with market caps generally between \$1.5 billion and \$10 billion.
  • Independent compensation consultant Pay Governance assists in peer benchmarking, market data analysis, and governance best practices.
• Director and Officer Compliance:
  • All but one executive officer, director, and greater-than-10% stockholder were in compliance with Section 16(a) reporting requirements. The only exception was a late Form 4 filing for Sinclair Dunlop relating to a June 24, 2025 stock transfer.
• No Incorporation by Reference: Unlike prior years, no definitive proxy statement information is being incorporated by reference. All disclosures are included in the current filing.

Implications for Investors and Share Price Sensitivity

• Governance Transparency: The Company’s proactive disclosure of board and governance practices, as well as the decision not to file a proxy statement, signals a commitment to transparency but may also raise questions about board processes and future stockholder engagement, especially regarding director elections and executive compensation votes.
• Executive Compensation Alignment: The strong “say-on-pay” support and emphasis on pay-for-performance may be viewed favorably by institutional investors, potentially supporting share price stability.
• Risk Management: The detailed description of risk oversight and committee responsibilities may reassure investors regarding the Company’s approach to enterprise risk, compliance, and audit integrity.
• Section 16(a) Compliance: The late filing by one director is not expected to be material but reflects attention to governance compliance.

Potential Price Sensitive Issues

• No Proxy Statement and Board Elections: The Company’s announcement that it will not file a proxy statement within 120 days and the inclusion of all Part III information directly in the 10-K/A may attract scrutiny from governance-focused investors and proxy advisory firms. Should this signal changes in board practices or future governance disputes, it could become a price-sensitive issue.
• Compensation Structure: The explicit focus on rigorous performance metrics and high equity-based pay for executives could affect stockholder perceptions, especially if future performance targets are missed or if market conditions change materially.

Conclusion

This 10-K/A filing is a crucial disclosure for Apellis Pharmaceuticals shareholders, encapsulating the Company’s governance and compensation philosophy, compliance status, and board structure. Investors should review these disclosures carefully as they may affect perceptions of corporate governance, executive accountability, and long-term value creation—and thus, potentially, Apellis’ share value.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should consult their own advisors and review official SEC filings directly before making investment decisions. The information herein is based on the Company’s public SEC filings as of April 28, 2026, and may not reflect subsequent events or changes.

View Apellis Pharmaceuticals, Inc. Historical chart here